#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians evaluating patients at clinical high risk for psychosis should assess for concurrent cannabis and tobacco use, as this combination appears to confer greater psychosis risk than either substance alone. This finding enables more precise stratification of CHR patients by risk level and could inform targeted prevention or early intervention strategies for those using both substances. Patients with CHR should receive counseling about the specific dangers of polysubstance use involving cannabis and tobacco, as the synergistic effect may outweigh warnings about single-substance use alone.
This study examined whether concurrent cannabis and tobacco use increases psychosis risk in individuals at clinical high risk (CHR) for psychotic disorders. The research found that co-use of both substances significantly predicted transition to psychosis compared to use of either substance alone or non-use, suggesting a synergistic rather than additive effect. The findings are particularly relevant for clinicians evaluating CHR patients, as the combination appears to represent a notably elevated risk profile that warrants heightened clinical attention and preventive intervention. This research underscores the importance of comprehensive substance use screening in at-risk populations, since identifying co-users may help clinicians stratify psychosis risk and guide more targeted counseling or monitoring strategies. Clinicians should specifically counsel CHR patients about the particular dangers of simultaneous cannabis and tobacco use rather than addressing these substances independently, as the interaction appears to substantially amplify psychiatric vulnerability in this vulnerable population.
“This peer-reviewed finding in a clinical high-risk population adds to our understanding of specific vulnerability patterns, though we need to be careful not to overextend it to general populations or assume causation rather than shared risk markers. In my practice, this reinforces why detailed substance use screening matters for patients showing early psychotic symptoms, especially when multiple substances are involved.”
💭 The finding that concurrent cannabis and tobacco use predicts psychosis onset in clinical high-risk populations has important screening implications, though clinicians should recognize that co-use frequency, potency of cannabis products, and underlying genetic vulnerability all represent significant confounders in this association. The mechanism driving this increased risk remains unclear—whether tobacco acts as a synergistic agent, both substances reflect shared liability, or co-use marks a more severely affected subgroup—limiting our ability to counsel patients with precision on relative harms. Additionally, the generalizability of findings from specialized CHR cohorts to routine clinical populations warrants caution, as these cohorts may enrich for individuals with greater psychiatric vulnerability or environmental stress. In clinical practice, this evidence suggests that routine substance use assessment in at-risk youth should specifically probe for both cannabis and tobacco use patterns rather than treating them as independent risk factors, and that individuals reporting co-use warrant closer psychotic symptom monitoring and
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
